Today: 3 July 2026
Why Nvidia’s $31 Billion Networking Business Is the Real Test of Its $1 Trillion AI Bet
19 March 2026
1 min read

Why Nvidia’s $31 Billion Networking Business Is the Real Test of Its $1 Trillion AI Bet

SAN JOSE, California, March 19, 2026, 02:04 PDT

Nvidia’s networking arm now tops $31 billion, carving out a strong second leg for the AI chip giant. The unit just hauled in $11 billion last quarter—over 3.5 times what it managed a year ago. As the company shakes off its headline $68 billion quarter, investors are turning to see how much fuel is left in the tank.

That’s become key as the conversation about Nvidia moves on. Selling GPUs is a given now; the focus has turned to whether Nvidia can lengthen the AI spending boom by moving whole systems — what it dubs AI factories, essentially data centers designed to train and deploy models, bundling compute, networking, and storage.

At Nvidia’s March 16 GTC event, Huang doubled down: the company now pegs a $1 trillion revenue opportunity for its Blackwell and Rubin chips through 2027, jumping from the $500 billion estimate for 2026. He referred to this as the “inference inflection”—meaning the pivot from training AI models to deploying them live in real-world use. Reuters

These are hefty figures. Nvidia clocked $68.1 billion in record quarterly revenue, with data center revenue hitting an all-time high of $62.3 billion for the quarter ended Jan. 25. CFO Colette Kress pointed to networking as “a standout,” noting customers ramped up purchases of scale-up and scale-out gear for massive clusters. NVIDIA Newsroom

Kevin Cook, a strategist at Zacks, pointed out to TechCrunch that Nvidia’s networking sales each quarter have now topped Cisco’s entire networking business—a sign of just how rapidly the segment has shifted from peripheral to central.

Inference work is a tougher battleground. Nvidia finds itself facing off with Intel’s CPUs, Google’s in-house chips, plus Chinese tech giants like Baidu. The company is racing to launch a Groq-based product that will meet China’s requirements and, according to Reuters, is also restarting some H200 production for the Chinese market.

This is the pocket of risk. Cleo Capital’s Sarah Kunst pointed out that after a stretch of hypergrowth, investors might have to get used to a “normal growth stage.” She cited stiffer year-over-year comps and headwinds from China, both factors that could drag on Nvidia’s quarterly fireworks—even if the company stays at the heart of AI capital flows. Still, fiscal 2026 revenue landed at $215.9 billion. 24/7 Wall St.

Nvidia slipped roughly 0.8% in Thursday’s session from its last close, according to the latest trading data.

On March 17, Huang clarified that the $1 trillion figure leaves out Nvidia’s CPUs, networking chips, Groq-derived offerings, and Rubin Ultra. Rubin-powered systems are set to arrive from Amazon Web Services, Google Cloud, Microsoft Azure, and Oracle in the latter half of 2026. That timeline puts a near-term spotlight on whether Nvidia’s expanded platform can push the story past chips alone.

Marcin Frąckiewicz is the founder and CEO of TS2 Space, a satellite communications company serving customers around the world. A graduate of the Warsaw School of Economics (SGH), he has more than two decades of experience in telecommunications, satellite services and technology ventures. He writes about satellite communications, space technology, artificial intelligence and the stock market, with a particular focus on technology companies, semiconductors, emerging industries and the trends shaping global innovation.

Stock Market Today

  • Raffles Medical Group (SGX:BSL) jumps after AI brain imaging partnership, valuation gap in focus
    July 3, 2026, 12:51 PM EDT. Raffles Medical Group (SGX:BSL) moved after a new partnership with Neurophet to provide AI software for brain MRI scans tied to neurodegenerative diseases. Shares traded at SGD0.93. The one-year shareholder return sits at -5.04%; year-to-date, the stock is down 8.82%. The P/E ratio is 24.3 times, which is below the peer group average of 29.4 but higher than the Asian healthcare industry's 19.9 and just above a calculated fair P/E of 23.8. A DCF model puts value 38.9% higher at SGD1.52, pointing to possible undervaluation. The market is weighing those potential gains against earnings risks and regulatory uncertainty in Singapore and Greater China.
Swarmer Stock Surges Again After IPO as Ukraine-Tested Drone Software Draws Wall Street
Previous Story

Swarmer Stock Surges Again After IPO as Ukraine-Tested Drone Software Draws Wall Street

Alibaba Stock Falls After Earnings Miss as AI Cloud Growth Fails to Offset China Price War
Next Story

Alibaba Stock Falls After Earnings Miss as AI Cloud Growth Fails to Offset China Price War

Go toTop